Novo Nordisk and Vivtex partner on oral metabolic therapies
Novo Nordisk and Vivtex Corporation have announced a partnership to develop oral biologic medicines for obesity, diabetes and associated comorbidities. Under the agreement, Vivtex will license select oral drug-delivery technologies to Novo Nordisk, while Vivtex is eligible to receive upfront payments totalling up to $2.1 billion, and… Read More